Literature DB >> 23153145

Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus.

Carrie Reed1, Caleb Bliss, Sherri O Stuver, Timothy Heeren, Sheila Tumilty, C Robert Horsburgh, Jeffrey H Samet, Deborah J Cotton.   

Abstract

OBJECTIVES: We investigated potential risk factors for active injection drug use (IDU) in an inner-city cohort of patients infected with hepatitis C virus (HCV).
METHODS: We used log-binomial regression to identify factors independently associated with active IDU during the first 3 years of follow-up for the 289 participants who reported ever having injected drugs at baseline.
RESULTS: Overall, 142 (49.1%) of the 289 participants reported active IDU at some point during the follow-up period. In a multivariate model, being unemployed (prevalence ratio [PR] = 1.93; 95% confidence interval [CI] = 1.24, 3.03) and hazardous alcohol drinking (PR = 1.67; 95% CI = 1.34, 2.08) were associated with active IDU. Smoking was associated with IDU but this association was not statistically significant. Patients with all 3 of those factors were 3 times as likely to report IDU during follow-up as those with 0 or 1 factor (PR = 3.3; 95% CI = 2.2, 4.9). Neither HIV coinfection nor history of psychiatric disease was independently associated with active IDU.
CONCLUSIONS: Optimal treatment of persons with HCV infection will require attention to unemployment, alcohol use, and smoking in conjunction with IDU treatment and prevention.

Entities:  

Mesh:

Year:  2012        PMID: 23153145      PMCID: PMC3518356          DOI: 10.2105/AJPH.2012.300819

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  43 in total

1.  Predictors of follow-up health status in the Drug Abuse Treatment Outcome Study (DATOS).

Authors:  Peter D Friedmann; Stephenie C Lemon; Bradley J Anderson; Michael D Stein
Journal:  Drug Alcohol Depend       Date:  2003-04-01       Impact factor: 4.492

Review 2.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

Review 4.  Global burden of disease (GBD) for hepatitis C.

Authors: 
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

5.  Drug use patterns over time among HIV-seropositive and HIV-seronegative women: the HER study experience.

Authors:  Grace E Macalino; Hyejin Ko; David D Celentano; Joseph W Hogan; Ellie E Schoenbaum; Paula Schuman; Josiah D Rich
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

6.  Nicotine and drug interaction expectancies among methadone maintained cigarette smokers.

Authors:  Michael D Stein; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2003-06

7.  Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants.

Authors:  N Galai; M Safaeian; D Vlahov; A Bolotin; D D Celentano
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

8.  Depression severity and drug injection HIV risk behaviors.

Authors:  Michael D Stein; David A Solomon; Debra S Herman; Bradley J Anderson; Ivan Miller
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

9.  Surveillance for acute viral hepatitis - United States, 2007.

Authors:  Danni Daniels; Scott Grytdal; Annemarie Wasley
Journal:  MMWR Surveill Summ       Date:  2009-05-22

10.  Nonadherence among HIV-infected injecting drug users: the impact of social instability.

Authors:  Anne-Déborah Bouhnik; Margaret Chesney; Patrizia Carrieri; Hervé Gallais; Jacques Moreau; Jean-Paul Moatti; Yolande Obadia; Bruno Spire
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

View more
  5 in total

1.  Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Authors:  Maryam Alavi; Tim Spelman; Gail V Matthews; Paul S Haber; Carolyn Day; Ingrid van Beek; Nick Walsh; Barbara Yeung; Julie Bruneau; Kathy Petoumenos; Kate Dolan; John M Kaldor; Gregory J Dore; Margaret Hellard; Jason Grebely
Journal:  Int J Drug Policy       Date:  2015-05-21

2.  Frequent Cannabis Use Is Negatively Associated with Frequency of Injection Drug Use Among People Who Inject Drugs in a Canadian Setting.

Authors:  Hudson Reddon; Kora DeBeck; Maria-Eugenia Socias; Stephanie Lake; Huiru Dong; Kanna Hayashi; Michael-John Milloy
Journal:  Cannabis Cannabinoid Res       Date:  2020-10-21

3.  Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment.

Authors:  Zahra Alam-Mehrjerdi; Afsaneh Moradi; Fenglian Xu; Mehran Zarghami; Javad Salehi-Fadardi; Kate Dolan
Journal:  Addict Health       Date:  2016-04

4.  Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs.

Authors:  Jacqueline Lim; Sureka Pavalagantharajah; Chris P Verschoor; Eric Lentz; Mark Loeb; Mitchell Levine; Marek Smieja; Lawrence Mbuagbaw; Dale Kalina; Jean-Eric Tarride; Tim O'Shea; Anna Cvetkovic; Sarah van Gaalen; Aidan Reid Findlater; Robin Lennox; Carol Bassim; Cynthia Lokker; Elizabeth Alvarez
Journal:  PLoS One       Date:  2022-04-20       Impact factor: 3.752

5.  Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol.

Authors:  Elizabeth Alvarez; Siddharth Joshi; Cynthia Lokker; Annie Wang; Sureka Pavalagantharajah; Yun Qiu; Hargun Sidhu; Lawrence Mbuagbaw; Majdi Qutob; Alia Henedi; Mitchell Levine; Robin Lennox; Jean-Eric Tarride; Dale Kalina
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.